Are FDA Penalties No Longer a “Slap on the Wrist?”
It's Friday and welcome again to the "Bob and John Blog Dialog" -- an ongoing series of informal back and forth jousting between DTC...
BMS’s “Oh, Yes I Can!” Ad is Reminescent of Obama’s “Yes We Can!” Slogan
In an ironic twist of advertising art imitating life, I noticed that Bristol-Meyers Squibb (BMS), marketer of the anti-arthritis drug Orencia, has trademarked the...
YAZ Commercial Yanked from TV, But Not from YouTube
Some time ago I pointed out that Bayer Healthcare Pharmaceuticals pulled its 60-second "Goodbye to You" ad for birth-control pill Yaz after the FDA...
10 Things I Hated (and Loved) about the ePharma Summit
I did not attend the ePharma Summit today -- I just had too much work to do here in the office taking care of...
ePharma Summit: Practicing What’s Being Preached!
After 4 days of R&R down in Miami, FL, I am back tending to my flock (of social networks, blogs, clients, subscribers) and trying...
Your Fortune: “Marketer Without Network Like Beached Whale”
Another Friday and another installment of the "Bob & John" show; ie, Bob Ehrlich (DTC Perspectives) and me, John Mack (Pharma Marketing News) debate...
FREE WebSeminar: Building the Optimal Service Model
Creating the Right Physician Experiences To Drive Business. The Vast Majority of Pharmaceutical Companies across the US and Europe Say They Are Moving from Traditional Sales Models to New Service Models. But Are Doctors Experiencing Any Real Change?
Pharma: Earn Back Your Trust Before Hell Freezes Over
Yesterday, I posted comments made by Pfizer's global PR chief, Ray Kerins, who asked "How in the hell do we have such a...
Pfizer’s PR Chief: “How in the hell do we have such a bad reputation?”
Over the past 20 months, Pfizer's global PR chief, Ray Kerins re-organized the company's press relations office to "manage" journalists, according to this 3-minute...
Sales Force Effectiveness Metrics: More Important Than Ever in a Tough Market
This article summarizes a recent discussion between eyeforpharma's Editor Lisa Roner and Hans Nagl, Promotion Response Modelling Manager, Shire, about how the current economy and changing pharma landscape is impacting program effectiveness measures.
